Expression of P.69/ppertactin from Bordetella pertussis in a baculovirus/insect cell expression system: protective properties of the recombinant protein

Charles, Ian G.; Rodgers, Brian; Musgrave, S.C.; Peakman, Timothy C.; Chubb, Ann; Fairweather, Neil F.; Dougan, Gordon; Roberts, Mark

doi:10.1016/0923-2508(93)90032-w

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(v) Neither active nor passive immunity to pertactin conferred protection to mice challenged i.c. (49). In one study, a relatively high dose of pertactin (16 μg) provided only incomplete immunity to mice challenged in the upper respiratory tract, whereas PTx conferred 100% protection at half that dose (8 μg) (50).…”

mentioning

confidence: 99%

Toward a new vaccine for pertussis

Robbins¹,

Schneerson²,

Kübler-Kiełb

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

To overcome the limitations of the current pertussis vaccines, those of limited duration of action and failure to induce direct killing of Bordetella pertussis , a synthetic scheme was devised for preparing a conjugate vaccine composed of the Bordetella bronchiseptica core oligosaccharide with one terminal trisaccharide to aminooxylated BSA via their terminal ketodeoxyoctanate residues. Conjugate-induced antibodies, by a fraction of an estimated human dose injected into young outbred mice as a saline solution, were bactericidal against B. pertussis , and their titers correlated with their ELISA values. The carrier protein is planned to be genetically altered pertussis toxoid. Such conjugates are easy to prepare, stable, and should add both to the level and duration of immunity induced by current vaccine-induced pertussis antibodies and reduce the circulation of B. pertussis .

show abstract

mentioning

confidence: 99%

Toward a new vaccine for pertussis

Robbins¹,

Schneerson²,

Kübler-Kiełb

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…38,39 Infection with B. parapertussis induces antipertactin antibodies but does not prevent pertussis. 43 Japanese regulatory agencies have requirements only for FHA and pertussis toxoid. The experience in Japan with acellular vaccines, where pertussis has almost been eradicated, indicates that pertactin is not essential for vaccine-induced immunity to pertussis.…”

Section: Does Pertactin Confer Immunity To Pertussis In Mice and In Hmentioning

confidence: 99%

Pertussis Vaccine

Robbins

Schneerson²,

Keith³

et al. 2009

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

A critical level of serum IgG pertussis toxin antibody is both essential and sufficient to confer individual and herd immunity to pertussis. Monocomponent pertussis toxoid conferred such immunity in Sweden and in Denmark. We refute the notion that filamentous hemagglutinin, pertactin, and fimbriae add to the immunity conferred by pertussis toxoid and describe the artifact created when efficacy is estimated for multicomponent pertussis vaccines. Lastly, the genetically-inactivated mutant pertussis toxoid is safer, more immunogenic, and should be more effective than the current chemically-inactivated pertussis toxin.

show abstract

Prevention of aggregate formation through mechanism analysis in refolding of recombinant pertactin from Escherichia coli

Zhang

et al. 2017

Process Biochemistry

View full text Add to dashboard Cite

Expression of P.69/ppertactin from Bordetella pertussis in a baculovirus/insect cell expression system: protective properties of the recombinant protein

Cited by 5 publications

References 25 publications

Toward a new vaccine for pertussis

Toward a new vaccine for pertussis

Pertussis Vaccine

Prevention of aggregate formation through mechanism analysis in refolding of recombinant pertactin from Escherichia coli

Contact Info

Product

Resources

About